SVB Leerink Downgrades Eidos Therapeutics (EIDX) to Market Perform, Following Acquisition
Tweet Send to a Friend
SVB Leerink analyst Mani Foroohar downgraded Eidos Therapeutics (NASDAQ: EIDX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
